So would I Sean. The heat map has reflected some interesting results. The results of the trial clearly show 350 mg is beneficial. It also shows 700 mg haplotype is beneficial. Are we missing something in the 700? Is something staring us in the face that no one has yet picked up on? Certainly, the solution should include both the use of 350 mg as well as 700 mg in the haplotype. maybe we will learn some more after this conference is done. I feel, the answer may be in the dosing and in the heat map but haven’t yet assembled the puzzle.